CY1113594T1 - Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης - Google Patents

Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης

Info

Publication number
CY1113594T1
CY1113594T1 CY20121100734T CY121100734T CY1113594T1 CY 1113594 T1 CY1113594 T1 CY 1113594T1 CY 20121100734 T CY20121100734 T CY 20121100734T CY 121100734 T CY121100734 T CY 121100734T CY 1113594 T1 CY1113594 T1 CY 1113594T1
Authority
CY
Cyprus
Prior art keywords
alpha
beta
phenyl
methoxy
ethyl
Prior art date
Application number
CY20121100734T
Other languages
English (en)
Inventor
Jean François Alexandre Lucas HEGYI
Wim Albert Alex Aelterman
Yolande Lydia Lang
Sigrid Carl Maria Stokbroekx
Carina Leys
Remoortere Peter Jozef Maria Van
Anne Faure
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113594(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1113594T1 publication Critical patent/CY1113594T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Abstract

Η παρούσα εφεύρεση αφορά το φουμαρικό άλας της (άλφα S, βήτα R)-6-βρωμο-άλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-άλφα-1-ναφθαλινυλ-βήτα-φαινυλ-3-κινολινοαιθανόλης, φαρμακευτικές συνθέσεις που περιλαμβάνουν ως δραστικό συστατικό το εν λόγω άλας και διεργασίες για την παρασκευή τους.
CY20121100734T 2006-12-05 2012-08-13 Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης CY1113594T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
EP07847697A EP2086940B1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
CY1113594T1 true CY1113594T1 (el) 2016-06-22

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100734T CY1113594T1 (el) 2006-12-05 2012-08-13 Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης

Country Status (34)

Country Link
US (1) US8546428B2 (el)
EP (1) EP2086940B1 (el)
JP (2) JP2010511663A (el)
KR (1) KR101514700B1 (el)
CN (2) CN105012303A (el)
AP (1) AP2498A (el)
AR (1) AR064149A1 (el)
AU (1) AU2007328945B2 (el)
BR (1) BRPI0719693A2 (el)
CA (1) CA2668512C (el)
CL (1) CL2007003472A1 (el)
CY (1) CY1113594T1 (el)
DK (1) DK2086940T3 (el)
EA (1) EA017091B9 (el)
ES (1) ES2387923T3 (el)
HK (1) HK1214513A1 (el)
HR (1) HRP20120639T1 (el)
IL (1) IL199077A (el)
JO (1) JO2973B1 (el)
ME (1) ME01456B (el)
MX (1) MX2009005909A (el)
MY (1) MY148844A (el)
NO (1) NO342773B1 (el)
NZ (1) NZ576485A (el)
PE (1) PE20081350A1 (el)
PL (1) PL2086940T3 (el)
PT (1) PT2086940E (el)
RS (1) RS52408B (el)
SI (1) SI2086940T1 (el)
TW (1) TWI417098B (el)
UA (1) UA97813C2 (el)
UY (1) UY30762A1 (el)
WO (1) WO2008068231A1 (el)
ZA (1) ZA200903907B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) * 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
SG11201705944TA (en) * 2015-01-27 2017-08-30 Janssen Pharmaceutica Nv Dispersible compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) * 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
RU2018111482A (ru) * 2015-10-20 2019-11-21 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Кристаллические формы бедаквилин фумарата и способы их получения
KR20230117248A (ko) * 2016-07-20 2023-08-07 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의용도
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
TW202233168A (zh) 2020-11-12 2022-09-01 比利時商健生藥品公司 治療非結核分枝桿菌疾病的藥物組分之組合
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
US5965572A (en) 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
CA2219070C (en) * 1996-10-30 2007-12-18 Eli Lilly And Company Methods of preventing breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
MXPA05001052A (es) * 2002-07-25 2005-04-08 Janssen Pharmaceutica Nv Derivados de quinolina y su uso como inhibidores micobacterianos.
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CN1976704B (zh) * 2004-05-28 2012-12-05 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
CA2577273C (en) * 2004-09-02 2013-11-19 Janssen Pharmaceutica N.V. Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법

Also Published As

Publication number Publication date
KR20090087020A (ko) 2009-08-14
EP2086940A1 (en) 2009-08-12
EA200970532A1 (ru) 2009-10-30
US20100028428A1 (en) 2010-02-04
EP2086940B1 (en) 2012-05-16
IL199077A (en) 2016-09-29
JP2015028049A (ja) 2015-02-12
UA97813C2 (uk) 2012-03-26
CN101547904A (zh) 2009-09-30
PT2086940E (pt) 2012-08-09
NZ576485A (en) 2012-01-12
SI2086940T1 (sl) 2012-09-28
HK1214513A1 (zh) 2016-07-29
CA2668512C (en) 2015-03-24
JO2973B1 (en) 2016-03-15
CN105012303A (zh) 2015-11-04
AP2498A (en) 2012-10-19
US8546428B2 (en) 2013-10-01
ME01456B (me) 2014-04-20
UY30762A1 (es) 2008-07-03
CA2668512A1 (en) 2008-06-12
HRP20120639T1 (hr) 2012-08-31
JP5894239B2 (ja) 2016-03-23
AU2007328945B2 (en) 2014-04-03
DK2086940T3 (da) 2012-08-20
MY148844A (en) 2013-06-14
PL2086940T3 (pl) 2012-10-31
TW200838527A (en) 2008-10-01
TWI417098B (zh) 2013-12-01
CL2007003472A1 (es) 2008-08-22
ES2387923T3 (es) 2012-10-04
EA017091B9 (ru) 2014-10-30
AU2007328945A1 (en) 2008-06-12
NO20092535L (no) 2009-08-06
AP2009004870A0 (en) 2009-06-30
JP2010511663A (ja) 2010-04-15
AR064149A1 (es) 2009-03-18
KR101514700B1 (ko) 2015-04-24
WO2008068231A1 (en) 2008-06-12
BRPI0719693A2 (pt) 2013-12-24
PE20081350A1 (es) 2008-09-18
MX2009005909A (es) 2009-06-16
NO342773B1 (no) 2018-08-06
ZA200903907B (en) 2013-08-28
RS52408B (en) 2013-02-28
EA017091B1 (ru) 2012-09-28

Similar Documents

Publication Publication Date Title
CY1113594T1 (el) Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
CY1122575T1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
CU20060038A7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
NO20092611L (no) Krystallinsk faststoff Rasagilin base
CU23616B7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
NO20090628L (no) Pyridizinon derivativater
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
NO20090175L (no) Stabile laquinimod sammensetninger
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
UY30759A1 (es) Compuestos quimicos
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
UY33075A (es) Derivados de ciclohexano y usos de los mismos
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης